好中球減少症:治療薬開発パイプライン分析

Global Markets Directが発行した調査報告書(GMDHC9728IDB)
◆英語タイトル:Neutropenia - Pipeline Review, H2 2017
◆商品コード:GMDHC9728IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年9月19日
◆ページ数:92
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における好中球減少症の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・好中球減少症の概要
・好中球減少症治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・好中球減少症パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・好中球減少症治療薬開発に取り組んでいる企業:企業別製品パイプライン
・好中球減少症治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Neutropenia – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia – Pipeline Review, H2 2017, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.

Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Neutropenia – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 4, 2, 2, 4, 6, 9 and 3 respectively.

Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Neutropenia – Overview 6
Neutropenia – Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 11
Neutropenia – Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Neutropenia – Companies Involved in Therapeutics Development 21
Adello Biologics LLC 21
Arven Ilac 21
BeyondSpring Pharmaceuticals Inc 21
Biocon Ltd 22
Cantex Pharmaceuticals Inc 22
Cellerant Therapeutics Inc 22
Cleveland BioLabs Inc 23
Coherus BioSciences Inc 23
Dr. Reddy’s Laboratories Ltd 24
Eurofarma Laboratorios SA 24
Ligand Pharmaceuticals Inc 25
Lupin Ltd 25
Merck & Co Inc 26
Mycenax Biotech Inc 26
Prolong Pharmaceuticals LLC 27
Richter Gedeon Nyrt 27
Sandoz International GmbH 28
USV Pvt Ltd 28
Neutropenia – Drug Profiles 29
ACN-8337 – Drug Profile 29
ARVMIC-02 – Drug Profile 30
CBLB-612 – Drug Profile 31
dociparstat sodium – Drug Profile 33
filgrastim – Drug Profile 35
filgrastim – Drug Profile 36
filgrastim – Drug Profile 37
filgrastim – Drug Profile 38
filgrastim – Drug Profile 39
LG-7455 – Drug Profile 40
pegfilgrastim – Drug Profile 41
pegfilgrastim – Drug Profile 43
pegfilgrastim – Drug Profile 44
pegfilgrastim – Drug Profile 45
pegfilgrastim – Drug Profile 46
pegfilgrastim – Drug Profile 47
pegfilgrastim – Drug Profile 48
pegfilgrastim – Drug Profile 51
pegfilgrastim – Drug Profile 52
pegfilgrastim – Drug Profile 53
pegfilgrastim – Drug Profile 54
pegfilgrastim – Drug Profile 55
pegfilgrastim – Drug Profile 56
pegfilgrastim – Drug Profile 57
pegfilgrastim (recombinant) – Drug Profile 58
plinabulin – Drug Profile 59
posaconazole – Drug Profile 65
romyelocel-L – Drug Profile 67
ST-7 – Drug Profile 70
tamibarotene – Drug Profile 71
Neutropenia – Dormant Projects 78
Neutropenia – Product Development Milestones 80
Featured News & Press Releases 80
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

List of Tables
Number of Products under Development for Neutropenia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Neutropenia - Pipeline by Adello Biologics LLC, H2 2017
Neutropenia - Pipeline by Arven Ilac, H2 2017
Neutropenia - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
Neutropenia - Pipeline by Biocon Ltd, H2 2017
Neutropenia - Pipeline by Cantex Pharmaceuticals Inc, H2 2017
Neutropenia - Pipeline by Cellerant Therapeutics Inc, H2 2017
Neutropenia - Pipeline by Cleveland BioLabs Inc, H2 2017
Neutropenia - Pipeline by Coherus BioSciences Inc, H2 2017
Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017
Neutropenia - Pipeline by Eurofarma Laboratorios SA, H2 2017
Neutropenia - Pipeline by Ligand Pharmaceuticals Inc, H2 2017
Neutropenia - Pipeline by Lupin Ltd, H2 2017
Neutropenia - Pipeline by Merck & Co Inc, H2 2017
Neutropenia - Pipeline by Mycenax Biotech Inc, H2 2017
Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, H2 2017
Neutropenia - Pipeline by Richter Gedeon Nyrt, H2 2017
Neutropenia - Pipeline by Sandoz International GmbH, H2 2017
Neutropenia - Pipeline by USV Pvt Ltd, H2 2017
Neutropenia - Dormant Projects, H2 2017
Neutropenia - Dormant Projects, H2 2017 (Contd..1), H2 2017

List of Figures
Number of Products under Development for Neutropenia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

【レポートのキーワード】

好中球減少症

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 好中球減少症:治療薬開発パイプライン分析(Neutropenia - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆